Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970421 | 0.85 | MGLL (0.44) | MGLLHDAC6P2RX7NAMPTSMO | |
| SCHEMBL5276608 | 0.79 | MGLL (0.44) | MGLLHDAC6 | |
| SCHEMBL22916873 | 0.78 | MGLL (0.45) | MGLLHDAC6P2RX7MET | |
| SCHEMBL16219062 | 0.78 | P2RX7 (0.53) | MGLLHDAC6P2RX7MET | |
| SCHEMBL20332081 | 0.73 | MGLL (0.47) | MGLLHDAC6P2RX7NAMPT | |
| SCHEMBL5497175 | 0.72 | DPP4 (0.63) | — | |
| SCHEMBL10674320 | 0.68 | MGLL (0.47) | MGLLHDAC6P2RX7NAMPTSMO | |
| SCHEMBL16219046 | 0.68 | SCD (0.46) | MGLLP2RX7NAMPTMET | |
| SCHEMBL16219018 | 0.68 | DPP4 (0.49) | MGLLNAMPTMETPARP1 | |
| SCHEMBL23011668 | 0.67 | MGLL (0.42) | MGLLHDAC6P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018224-B2 | Substituted cyclopropyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | GPR119, GPR27, GCGR | MGLL 758/4885HDAC6 3582/4885P2RX7 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.